Search clinical trials for: ACT-334441 4 mg

Total 672 results

Idorsia Pharmaceuticals Ltd.

Recruiting

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

Lupus Erythematosus, Systemic

Spain, United States, Georgia, Serbia, Germany, Portugal, Poland, South Africa, Philippines, Czechia, Puerto Rico, Chile, Japan, Peru
Idorsia Pharmaceuticals Ltd.

Recruiting

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Healthy | Hepatic Impairment

Portugal, Hungary
Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Healthy | Renal Impairment

Portugal
Idorsia Pharmaceuticals Ltd.

Recruiting

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

Lupus Erythematosus, Systemic

Taiwan, United States, Korea, Republic of, Poland, Greece, Philippines, Romania, Bulgaria, Argentina, France, Mexico
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Belarus, Bulgaria, Georgia, Russian Federation, Ukraine
Idorsia Pharmaceuticals Ltd.

Terminated

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Healthy Subjects

France
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

Healthy Subjects

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Acute Myocardial Infarction

Switzerland, Israel, Belgium
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Withdrawn

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. (INSPIRE-CKD)

Hypertension | Renal Insufficiency, Chronic
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Spain, United States, Italy, Taiwan, Thailand, Poland, Russian Federation, Israel, Ukraine, Mexico, Philippines, Georgia, United Kingdom, Chile, France, Bulgaria, Czechia, Greece, Hungary, Romania, Turkey, Germany, Puerto Rico, Japan
Duke University
National Institute of Allergy and Infectious Diseases (NIAID); Moi University; Clinton Health Access Initiative, Nigeria

Completed

Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1 (TESTsmART)

Malaria | Febrile Illness

Kenya
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (CONSCIOUS-1)

Aneurysmal Subarachnoid Hemorrhage

United States, Canada
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Midnight Pharma, LLC

Completed

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Chronic Primary Insomnia

United States
Chulalongkorn University

Not yet recruiting

Efficacy and Safety of Astaxanthin in Volunteer With Refraction Errors

Refractive Errors
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Aaron R. Mangold

Completed

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Cutaneous Lichen Planus

United States
Acorda Therapeutics

Completed

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Zydus Therapeutics Inc.

Recruiting

Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US (SARONAPLUS)

Nonalcoholic Steatohepatitis

United States
Vanderbilt University Medical Center
Yale University; Emory University; University of California, San Francisco; Vanderbilt... and other collaborators

Not yet recruiting

REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)

Post-Acute COVID-19 Syndrome

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

France
Ixchelsis Limited

Completed

Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males (IX-0106 RBA)

Healthy

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
Stealth BioTherapeutics Inc.

Completed

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Heart Failure

Netherlands, Italy, United Kingdom
Zydus Therapeutics Inc.

Suspended

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Dyslipidemias

United States
University of Alabama at Birmingham
Eli Lilly and Company

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Frontal Fibrosing Alopecia

United States
Steba Biotech S.A.

Active, not recruiting

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Localized Prostate Cancer

United States
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
Gannex Pharma Co., Ltd.

Withdrawn

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Nonalcoholic Steatohepatitis (NASH)
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

Healthy

Indonesia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Merck Sharp & Dohme LLC

Terminated

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Anemia | Bladder Cancer | Cancer of Head and Neck | Uterine Cervical Cancer | Carcinoma, Small-Cell Lung
University Hospital, Rouen

Not yet recruiting

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE)

Active Non-anterior Non-infectious Uveitis
AstraZeneca

Active, not recruiting

A Study of CIN-107 in Adults With Primary Aldosteronism

Primary Aldosteronism | Hyperaldosteronism

United States
Idorsia Pharmaceuticals Ltd.

Terminated

Clazosentan in Aneurysmal Subarachnoid Hemorrhage (CONSCIOUS-3)

Aneurysmal Subarachnoid Hemorrhage

United States, Belgium, Taiwan, Canada, Hong Kong, Singapore, Germany, Netherlands, India, Czechia, Switzerland, France, Australia, Spain, Denmark, Finland, Argentina, Brazil, Sweden, Austria, Chile, Hungary, Israel, Italy, Mexico, Norway, ... and more
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees

Knee Osteoarthritis
Vantia Ltd

Completed

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Nocturia

United States

3

Subscribe